Armata Pharmaceuticals (ARMP) Operating Expenses (2013 - 2026)

Armata Pharmaceuticals has disclosed Operating Expenses across 14 years of filings, most recently posting $9.6 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $9.6 million, up 10.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $42.4 million (down 5.92% YoY), and the FY2025 annual result was $41.5 million, down 12.75% from the prior year.
• Operating Expenses came in at $9.6 million for Q1 2026 at Armata Pharmaceuticals, down from $14.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $14.9 million in Q4 2025 to a low of $8.7 million in Q1 2025.
• The 5-year median for Operating Expenses is $11.1 million (2023), against an average of $11.0 million.
• Across the five-year window, Operating Expenses jumped 61.7% in 2022 and slipped 29.81% in 2025, its largest moves.
• Armata Pharmaceuticals' Operating Expenses stood at $11.4 million in 2022, then fell by 2.39% to $11.1 million in 2023, then grew by 6.01% to $11.8 million in 2024, then climbed by 26.62% to $14.9 million in 2025, then sank by 35.78% to $9.6 million in 2026.
• The last three Operating Expenses figures came in at $9.6 million (Q1 2026), $14.9 million (Q4 2025), and $8.9 million (Q3 2025), per Business Quant data.